Review
Biochemistry & Molecular Biology
Florus C. de Jong, Vera C. Rutten, Tahlita C. M. Zuiverloon, Dan Theodorescu
Summary: PD-1/PD-L1 immune checkpoint inhibitors show promise in high-risk non-muscle invasive bladder cancer and muscle-invasive bladder cancer, but challenges such as biomarkers for response stratification and potentially synergistic combination therapy regimens with PD-1/PD-L1 blockade need to be addressed to improve patient outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Immunology
Rilan Bai, Jiuwei Cui
Summary: Antibodies targeting PD-1/PD-L1 have been considered breakthrough therapies for cancer. In addition to T cell-driven immune responses, blocking PD-1/PD-L1 may also enhance the function and activity of NK cells, which are often overlooked in previous studies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Plant Sciences
Myong Hak Ri, Juan Ma, Xuejun Jin
Summary: This study reviews the pharmacological effects of natural products, raw extracts, and traditional medicines associated with the PD-1/PD-L1 axis in cancer immunotherapy, particularly focusing on PD-L1. It was found that several natural products and traditional medicines have diverse and multi-functional effects that can improve strategies for anti-PD-1/PD-L1 therapy, but further research and exploration are needed.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Review
Immunology
Andrea Botticelli, Alessio Cirillo, Lidia Strigari, Filippo Valentini, Bruna Cerbelli, Simone Scagnoli, Edoardo Cerbelli, Ilaria Grazia Zizzari, Carlo Della Rocca, Giulia D'Amati, Antonella Polimeni, Marianna Nuti, Marco Carlo Merlano, Silvia Mezi, Paolo Marchetti
Summary: This study compared the efficacy of anti-PD-1 and anti-PD-L1-based therapy in R/M HNSCC patients through a systematic review and network meta-analysis. It found no significant differences in overall survival between different subgroups, except for metastatic patients where anti-PD-1-based therapy was associated with significantly less risk of death.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Duaa Alkaabi, Kholoud Arafat, Shahrazad Sulaiman, Aya Mudhafar Al-Azawi, Samir Attoub
Summary: Triple-negative breast cancer (TNBC) is a highly aggressive type of breast cancer with poor prognosis. This study investigated the role of programmed death-ligand 1 (PD-L1) in TNBC MDA-MB-231 cells independent of its binding to PD-1 receptors on T cells. The study found that knockout of PD-L1 inhibited cell proliferation, colony formation, migration, and invasion in vitro, as well as tumor growth in a chick embryo model in vivo. PD-L1 knockout also affected the expression of several downstream proteins involved in tumor progression. These findings suggest that targeting PD-L1 could be a potential therapeutic strategy for TNBC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biotechnology & Applied Microbiology
Xiaoli Hu, Jing Wang, Man Chu, Yi Liu, Zhi-wei Wang, Xueqiong Zhu
Summary: The ubiquitination and deubiquitination of PD-1/PD-L1 play crucial roles in modulating immune escape and tumor clearance, with abnormal ubiquitination influencing immune suppression. Targeting PD-1/PD-L1 ubiquitination may offer a promising therapeutic approach for cancer immunotherapy.
Article
Biotechnology & Applied Microbiology
Nian Liu, JiangLin Zhang, Mingzhu Yin, Hong Liu, Xu Zhang, Jiaoduan Li, Bei Yan, Yeye Guo, Jianda Zhou, Juan Tao, Shuo Hu, Xiang Chen, Cong Peng
Summary: The study demonstrated that inhibiting xCT may be a promising therapeutic strategy for melanoma, but it also reduces the efficacy of anti-PD-1/PD-L1 treatment by inducing PD-L1 expression and M2 macrophage polarization. Further research is needed to understand the impact of glutamate metabolism on tumor progression and immunotherapy outcomes.
Article
Multidisciplinary Sciences
Changsheng Huang, Shengxiang Ren, Yaqi Chen, Anyi Liu, Qi Wu, Tao Jiang, Panjing Lv, Da Song, Fuqing Hu, Jingqing Lan, Li Sun, Xue Zheng, Xuelai Luo, Qian Chu, Keyi Jia, Yan Li, Jun Wang, Caicun Zou, Junbo Hu, Guihua Wang
Summary: This research discovered that PD-L1 K162 was methylated by SETD7 and demethylated by LSD2. Additionally, PD-L1 K162 methylation controlled the PD1/PD-L1 interaction and significantly enhanced the suppression of T cell activity in controlling cancer immune surveillance. The study demonstrated that PD-L1 hypermethylation was the key mechanism for anti-PD-L1 therapy resistance, identified PD-L1 K162 methylation as a negative predictive marker for anti-PD-1 treatment in patients with non-small cell lung cancer, and showed that the PD-L1 K162 methylation:PD-L1 ratio was a more accurate biomarker for predicting anti-PD-(L)1 therapy sensitivity.
Review
Biochemistry & Molecular Biology
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Rocio Granda-Diaz, Alejandra Martinez-Perez, Candelaria Aguilar-Garcia, Juan P. Rodrigo, Juana M. Garcia-Pedrero, Segundo Gonzalez
Summary: The introduction of monoclonal antibodies targeting immune checkpoints has greatly impacted cancer treatment. However, limited overall responses and the lack of predictive biomarkers for patient response are major challenges in immunotherapy. Therefore, it is important to identify novel targets for immunotherapy to expand the range of strategies and improve therapeutic efficacy for cancer patients.
Review
Biochemistry & Molecular Biology
Wenxiao Jiang, Shuya Pan, Xin Chen, Zhi-wei Wang, Xueqiong Zhu
Summary: The focus of the study is on understanding the regulatory roles of long noncoding RNAs and circular RNAs in the PD-1/PD-L1 pathway, in hopes of driving more precise and effective cancer immune checkpoint therapies.
Review
Biochemistry & Molecular Biology
Xianzhe Yu, Xiaoqian Zhai, Juan Wu, Qingbo Feng, Chenggong Hu, Lingling Zhu, Qinghua Zhou
Summary: Gastric cancer is a global health problem, and traditional therapies have limited efficacy. Immunotherapy using checkpoint inhibitors, particularly therapeutic antibodies targeting the PD-1/PD-L1 pathway, has made substantial breakthroughs in the treatment of gastric cancer.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2024)
Review
Immunology
Zhengyang Yang, Guocong Wu, Xiao Zhang, Jiale Gao, Cong Meng, Yishan Liu, Qi Wei, Liting Sun, Pengyu Wei, Zhigang Bai, Hongwei Yao, Zhongtao Zhang
Summary: Immunotherapies, especially PD-1/PD-L1 inhibitors, have revolutionized cancer treatment. Their effectiveness in CRC depends on the mutation pattern, and combining them with other treatments has been proposed for better therapeutic effect. Neoadjuvant therapy, including chemotherapy and radiotherapy, can improve clinical symptoms and life quality. Incorporating immunotherapy into neoadjuvant therapy may shift the treatment strategy for some CRC patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Ander Puyalto, Maria Rodriguez-Remirez, Ines Lopez, Fabiola Iribarren, Jon Ander Simon, Marga Ecay, Maria Collantes, Anna Vilalta-Lacarra, Alejandro Francisco-Cruz, Jose Luis Solorzano, Sergio Sandiego, Ivan Penuelas, Alfonso Calvo, Daniel Ajona, Ignacio Gil-Bazo
Summary: This study demonstrates the use of [Zr-89]-anti-PD-1 immuno-PET as a safe and feasible imaging modality to accurately assess the response to PD-1/PD-L1 blockade in NSCLC.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Luyao Wang, Zongxing Yang, Fucheng Guo, Yurong Chen, Jiarui Wei, Xiangpeng Dai, Xiaoling Zhang
Summary: Currently, anti-PD-1/PD-L1 immunotherapy is widely used for treating lung cancer, but only a limited proportion of patients benefit from it. Therefore, it is important to predict the response to immunotherapy. PD-L1 expression, tumor mutation burden, tumor-specific genes, dMMR/MSI, and gut microbiome have been studied as potential predictors. In addition, invasive blood biomarkers such as ctDNA, immune cells, and cytokines have also been used. This review summarizes the achievements and potential biomarkers for predicting the response to anti-PD-1/PD-L1 immunotherapy in lung cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Yiru Long, Xiaolu Yu, Runqiu Chen, Yongliang Tong, Likun Gong
Summary: With programmed death 1/ligand 1 (PD-1/PD-L1) as the cornerstone, anti-PD antibodies have revolutionized immunotherapies for malignancies. However, many patients fail to respond to anti-PD treatment due to resistance or hyperprogression. The study highlights the importance of noncanonical PD-1/PD-L1 expression in various cancers and its impact on the efficacy of anti-PD antibodies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
James R. Patrinely, Laura X. Baker, Elizabeth J. Davis, Haocan Song, Fei Ye, Douglas B. Johnson
Article
Hematology
Inga Saknite, Zijun Zhao, J. Randall Patrinely, Michael Byrne, Madan Jagasia, Eric R. Tkaczyk
Article
Surgery
J. Randall Patrinely, Matthew J. Davis, Amjed Abu-Ghname, Edward M. Reece, Galen Perdikis
ANNALS OF PLASTIC SURGERY
(2020)
Letter
Dermatology
J. Randall Patrinely, Anna K. Dewan
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Ophthalmology
J. Randall Patrinely, Kristy L. Hamilton, Robert B. Parke, James R. Patrinely, Charles N. S. Soparkar
Summary: Through a retrospective study, the relationship between supraorbital neuralgia (SON) and thyroid eye disease (TED) was identified, with SON being a significant but underreported pain associated with TED. Supraorbital nerve block was effective in relieving pain in patients with SON, who were also more likely to undergo orbital decompression. Contrary to standard rating scales, the presence of SON was associated with an increased likelihood of both orbital decompression and TED reactivation.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
(2021)
Article
Oncology
J. Randall Patrinely, Elisa Funck-Brentano, Khang Nguyen, Suthee Rapisuwon, Joe-Elie Salem, Geoffrey T. Gibney, Matteo Carlino, Douglas B. Johnson
Summary: The study characterizes outcomes of patients with isolated brain metastases managed with local therapy followed by immune checkpoint inhibitor (ICI) therapy. Patients who underwent surgery or SRS for isolated brain metastases appeared to benefit from adjuvant ICI therapy, particularly with combination therapy. Recurrences in this setting largely occur intracranially.
Article
Dermatology
Danny Zakria, James R. Patrinely, Anna K. Dewan, Sharon E. Albers, Lee E. Wheless, Aleta N. Simmons, Brian C. Drolet
Summary: Corticosteroid injections are effective in treating dermatologic pathologies with relatively low associated pain. However, the study found that adding lidocaine with epinephrine to the injection may increase injection pain.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Surgery
J. Randall Patrinely, Sallie H. Walker, Gabriella E. Glassman, Matthew J. Davis, Amjed Abu-Ghname, Umraz Khan, Brian C. Drolet, Antonio J. Forte, Galen Perdikis
Summary: This study identified the importance of using key performance indicators in surgical funding requests. Understanding metrics such as collections, contribution margin, and operating room cases is crucial for a successful financial outcome. Surgeons should advocate for increased transparency to better understand their financial contributions and performance.
PLASTIC AND RECONSTRUCTIVE SURGERY
(2021)
Article
Surgery
Eva B. Niklinska, Juan M. Colazo, James Randall Patrinely, Brian C. Drolet, Salam A. Kassis
Summary: Most patients undergoing PMFF surgery experienced a change in headache quality post-surgery, suggesting a potential connection between SON and STN pathology and HA/MH pathophysiology, indicating further research is needed.
Article
Oncology
J. Randall Patrinely, Rebecca Johnson, Aleigha R. Lawless, Prachi Bhave, Amelia Sawyers, Maya Dimitrova, Hui Ling Yeoh, Marisa Palmeri, Fei Ye, Run Fan, Elizabeth J. Davis, Suthee Rapisuwon, Georgina V. Long, Andrew Haydon, Iman Osman, Janice M. Mehnert, Matteo S. Carlino, Ryan J. Sullivan, Alexander M. Menzies, Douglas B. Johnson
Summary: This multicenter cohort study found that chronic immune-related adverse events (irAEs) associated with anti-PD-1 therapy were more common than previously recognized, with a considerable proportion of patients developing chronic irAEs such as endocrinopathies and arthritis. Visceral organ-related irAEs had lower rates of becoming chronic, highlighting the importance of considering the risks of chronic irAEs in treatment decision-making.
Article
Hematology
Zijun Zhao, James Randall Patrinely, Inga Saknite, Michael Byrne, Eric R. Tkaczyk
Summary: The study aimed to develop a guideline for accurately identifying cutaneous adherent and rolling leukocytes in vivo using reflectance confocal videomicroscopy. By implementing this guideline, the inter-rater reliability of leukocyte counts improved significantly, indicating enhanced accuracy in manual assessment of leukocyte-endothelial interactions.
Article
Oncology
Patricio Serra-Bellver, Judith M. Versluis, Honey K. Oberoi, Cong Zhou, Timothy D. Slattery, Yasir Khan, James R. Patrinely, Ines Pires da Silva, C. Martinez-Vila, Natalie Cook, Donna M. Graham, Matteo S. Carlino, Alexander M. Menzies, Ana M. Arance, Douglas B. Johnson, Georgina Long, Lisa Pickering, James M. G. Larkin, Christian U. Blank, Paul Lorigan
Summary: This retrospective study assessed the efficacy and toxicity of combination immunotherapy with ipilimumab and nivolumab in patients with advanced melanoma. The results demonstrated that this treatment regimen achieved similar treatment outcomes and adverse events in real-world patient population as reported in pivotal trials.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
J. Randall Patrinely, Ben McGuigan, Sunandana Chandra, Sarah E. Fenton, Akansha Chowdhary, Lucy B. Kennedy, Meghan J. Mooradian, Marisa Palmeri, Daniella Portal, Sara N. Horst, Elizabeth A. Scoville, Georgina Long, Chanjuan Shi, Janice M. Mehnert, Ryan J. Sullivan, April K. Salama, Jeffrey A. Sosman, Alexander M. Menzies, Douglas B. Johnson
Summary: Immune-related hepatitis associated with immune checkpoint inhibitors has a median onset time of around two months, with most patients being asymptomatic or experiencing flu-like symptoms. Treatment usually involves glucocorticoids and second-line immunosuppression, with a modest risk of hepatitis recurrence when rechallenging with ICI therapy.
Article
Dermatology
James Randall Patrinely, Charles Darragh, Nicholas Frank, Brandon C. Danford, Lee Wheless, Anna Clayton
Summary: A retrospective review of 563 patients who received over 30 mL of locally injected lidocaine from 1992 to 2016 showed complication rates of 1.4% on the day of surgery and 4.4% within 7 days post-surgery, with excessive bleeding/hematoma formation and wound infection being the most common complications. Only two complications could be attributed to local anesthetics, and gender, heart disease, hypertension, diabetes, and smoking were not significant risk factors for complications.
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2021)